Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial

Arthritis and Rheumatism
John H StoneWegener's Granulomatosis Etanercept Trial Research Group

Abstract

Etanercept is a soluble fusion protein designed to inhibit tumor necrosis factor (TNF). During the Wegener's Granulomatosis Etanercept Trial (WGET), a placebo-controlled trial of etanercept given in addition to standard therapy for remission induction and maintenance, more solid malignancies were observed in the etanercept group than in the group treated with standard therapy alone. This study was undertaken to further explore the potential association between anti-TNF therapy and the development of malignancy in these patients. One hundred eighty patients with active WG were enrolled and followed up for a median of 27 months. At enrollment, disease characteristics, treatment history, specific medical history items, and information about previous WG treatments and risk factors for malignancy were recorded. During the trial, the occurrence of malignancies and other adverse events was recorded prospectively. All 6 solid malignancies observed during the WGET occurred in the etanercept group (P = 0.01 versus placebo group); based on a comparison of age- and sex-specific incidence rates, 1.92 solid malignancies would have been expected in this group. The solid malignancies included 2 cases of mucinous adenocarcinoma of the colon, 1 ...Continue Reading

Associated Clinical Trials

References

Sep 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·E A CarswellB Williamson
Oct 31, 1998·Current Opinion in Immunology·F J LejeuneD Liénard
Apr 22, 1999·Arthritis and Rheumatism·E TatsisW L Gross
Apr 25, 2001·Arthritis and Rheumatism·J H StoneUNKNOWN International Network for the Study of the Systemic Vasculitides (INSSYS)
May 3, 2002·The New England Journal of Medicine·Jennifer D GormanJohn C Davis
Jul 13, 2002·International Journal of Cancer. Journal International Du Cancer·Ann KnightAnders Ekbom
Aug 6, 2002·Controlled Clinical Trials·UNKNOWN WGET Research Group
Jun 11, 2003·Chest·Celso T EbeoJay B Mehta
Jun 18, 2003·Annals of the Rheumatic Diseases·C D CohenJ R Bogner
Jun 27, 2003·Rheumatology·G Bakland, H Nossent
Aug 2, 2003·The British Journal of Dermatology·E MahéB Crickx
Aug 9, 2003·Arthritis and Rheumatism·John H Stone, UNKNOWN Wegener's Granulomatosis Etanercept Trial Research Group
Nov 25, 2003·The New England Journal of Medicine·Craig L LeonardiUNKNOWN Etanercept Psoriasis Study Group
Nov 26, 2003·The American Journal of Gastroenterology·Guillermo AlcaínEduardo Franquelo
Feb 27, 2004·The New England Journal of Medicine·Bruce E SandsSander J van Deventer
Apr 21, 2004·Journal of the American Academy of Dermatology·Adam C EsserJohn A Doyle
May 8, 2004·Annals of the Rheumatic Diseases·A KnightA Ekbom
May 21, 2004·The New England Journal of Medicine·Nancy J Olsen, C Michael Stein
Jun 3, 2004·Rheumatic Diseases Clinics of North America·Sir Ravinder Maini
Jun 10, 2004·Arthritis and Rheumatism·Deborah P M Symmons, Alan J Silman
Aug 19, 2004·Rheumatology·T PankhurstL Harper
Jan 28, 2005·The New England Journal of Medicine·UNKNOWN Wegener's Granulomatosis Etanercept Trial (WGET) Research Group
Feb 3, 2005·Annals of Internal Medicine·Axel Finckh, Mark D Aronson
Mar 25, 2005·The New England Journal of Medicine·Susan Okie

❮ Previous
Next ❯

Citations

Apr 12, 2007·Clinical Reviews in Allergy & Immunology·Loïc GuillevinLuc Mouthon
Apr 9, 2009·Rheumatology International·Serpil Muge DegerSukru Sindel
Nov 4, 2010·Clinical Rheumatology·Chi Chiu MokUNKNOWN Hong Kong Society of Rheumatology
Mar 12, 2009·Medical Oncology·Inès ZidiNidhal Ben Amor
Apr 8, 2010·Medical Oncology·Ines ZidiNidhal Ben Amor
Mar 20, 2013·Best Practice & Research. Clinical Rheumatology·Alfred MahrMikkel Faurschou
May 29, 2008·Nature Clinical Practice. Rheumatology·Carol A Langford
Apr 23, 2009·Nature Reviews. Nephrology·Lalit PallanLorraine Harper
Oct 13, 2011·Nature Reviews. Rheumatology·Kevin L Winthrop, Josef S Smolen
Jul 22, 2010·The New England Journal of Medicine·John H StoneUNKNOWN RAVE-ITN Research Group
Dec 5, 2006·Current Opinion in Rheumatology·Cees Gm Kallenberg
Feb 19, 2008·Current Opinion in Rheumatology·Philip Seo
Feb 19, 2008·Current Opinion in Rheumatology·David Jayne
Apr 5, 2008·Current Opinion in Rheumatology·Johan Askling, Tim Bongartz
Mar 7, 2012·Medicine·Jean-François DufourUNKNOWN French Vasculitis Study Group
May 16, 2009·Current Opinion in Hematology·Bryan R Whelan, David A Isenberg
Oct 29, 2008·Acta Pharmacologica Sinica·Xia Wang, Yong Lin
Oct 14, 2006·Annals of the Rheumatic Diseases·D E FurstM H Weisman
Nov 21, 2007·Annals of the Rheumatic Diseases·D E FurstM E Weinblatt
Feb 1, 2011·Therapeutic Advances in Musculoskeletal Disease·Tanaz A KermaniShreyasee Amin
Feb 24, 2009·Arthritis Research & Therapy·Vibeke Strand, Jeremy Sokolove
Jul 5, 2011·Arthritis Research & Therapy·Katarzyna Elandt, Daniel Aletaha
May 10, 2012·Arthritis Research & Therapy·Rona M SmithDavid R W Jayne
Mar 25, 2008·Therapeutics and Clinical Risk Management·Kim A Papp
Apr 27, 2007·Allergology International : Official Journal of the Japanese Society of Allergology·Shoichi Ozaki
Jul 31, 2013·Blood Cells, Molecules & Diseases·Wei DuQishen Pang
Jun 24, 2008·La Revue de médecine interne·P Gaudin
Jul 2, 2014·Nature Reviews. Rheumatology·Cees G M Kallenberg
Aug 13, 2014·Nature Reviews. Rheumatology·Onur BoymanFrançois Spertini
May 3, 2011·The American Journal of Medicine·Daniel E FurstUNKNOWN Scleroderma Lung Study
Jul 15, 2006·Current Rheumatology Reports·Pasha SarrafAnthony M Reginato
Aug 11, 2007·Current Rheumatology Reports·Carol A Langford
Sep 8, 2012·Current Rheumatology Reports·Francisco SilvaUlrich Specks
Nov 1, 2007·Expert Review of Clinical Immunology·Chetan MukhtyarRaashid Luqmani
Mar 1, 2007·Expert Review of Clinical Immunology·Shanu Kohli KurdJoel M Gelfand
Jul 1, 2008·Expert Review of Clinical Immunology·R MannaG Paludetti
Apr 28, 2007·Expert Opinion on Investigational Drugs·Umut SelametLorraine Harper
Jul 11, 2008·Expert Opinion on Drug Safety·Martin Aringer, Josef S Smolen
Jun 15, 2007·Expert Opinion on Pharmacotherapy·T Cobo-Ibáñez, E Martín-Mola
Dec 15, 2010·Kidney International·Benjamin WildeJan Willem Cohen Tervaert
May 14, 2009·Kidney International·Thomas Ernandez, Tanya N Mayadas
Mar 8, 2016·Nature Reviews. Nephrology·Stephen R HoldsworthA Richard Kitching
Nov 1, 2007·Dermatologic Therapy·J Mark Jackson
Sep 7, 2007·Annals of the New York Academy of Sciences·Luis Felipe Flores-Suárez, Antonio R Villa

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.